Four cases of anti-Mi-2 antibody-positive dermatomyositis: relationship between anti-Mi-2 antibody titer and disease severity and activity

Abstract

Anti-Mi-2 antibody was found to be a specific marker for dermatomyositis (DM) [1, 2]. Patients with anti-Mi-2 antibody generally have a more favorable prognosis, such as milder muscle involvement and a lower risk of interstitial lung disease (ILD) and malignancy [3, 4]. However, it currently remains unclear whether the anti-Mi-2 antibody titer correlates with disease severity and activity, or if repeated testing for disease monitoring is beneficial.

This article is protected by copyright. All rights reserved.